ArticleMolecular biology reports2026
Synergistic restoration of NK cell cytotoxicity against solid tumors via sLTA-mediated dual-action modulation.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundNatural killer (NK) cell-based immunotherapy has shown limited efficacy against solid tumors due to impaired NK cell activation and intrinsic tumor resistance. This study investigated whether lipoteichoic acid isolated from Latilactobacillus sakei K101 (sLTA) could overcome NK resistance in HT-29 colon cancer cells. METHODS AND
resultsUsing an NK3.3/HT-29 co-culture system, we found that IL-2-activated NK cells alone were insufficient to induce robust cytotoxicity, whereas sLTA restored NK-mediated tumor cell killing. sLTA upregulated NK activating receptors, including NKG2D and natural cytotoxicity receptors, while enhancing MICB expression and suppressing Bcl-2 and other anti-apoptotic genes in HT-29 cells. siRNA-mediated knockdown and Western blot analysis confirmed the involvement of Caspase-3-dependent apoptosis. Transwell and neutralization assays further demonstrated that sLTA-primed HT-29 cells were sensitized to contact-independent cytotoxicity mediated by NK-derived TNF-α and IFN-γ.
conclusionssLTA functions as a dual-action immune sensitizer by enhancing NK effector activation and lowering the apoptotic threshold of resistant tumor cells. These findings suggest that sLTA may serve as an adjunct strategy to improve NK cell-based immunotherapy against solid tumors.
Indexed as
Identifiers
42747644What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.